Oteiza y Malévich. El proyecto de cementerio Izarrak Alde (del lado de las estrellas) para Ametzagaña

539 p.; 261 p.(anexos)

Hacia el encuentro de mi anthropos: la muerte, dinamo estructural de la vida

559 p. - Sobresaliente cum laudem por unanimidad. La presidenta del tribunal hace la petición al departamento, en el acto de calificación de la defensa, de publicación de esta tesis por considerarla de interés científico.

[A_Labraza_Muralla] Documentación geométrica y restitución fotogramétrica de la muralla exterior de Labraza. Álava

[ES] Se han documentado unos 180 metros de muralla que corresponde a los alzados este y norte. También se incluye el interior de dos puertas de acceso, el muro exterior del cementerio y parte de los muros de la iglesia.

Differential Neuroprotective Effects of 5 '-Deoxy-5 '-Methylthioadenosine

Background: 5'-deoxy-5'-methylthioadenosine (MTA) is an endogenous compound produced through the metabolism of polyamines. The therapeutic potential of MTA has been assayed mainly in liver diseases and, more recently, in animal models of multiple sclerosis. The aim of this study was to determine the neuroprotective effect of this molecule in vitro and to assess whether MTA can cross the blood brain barrier (BBB) in order to also analyze its potential neuroprotective efficacy in vivo. Methods: Neuroprotection was assessed in vitro using models of excitotoxicity in primary neurons, mixed astrocyte-neuron and primary oligodendrocyte cultures. The capacity of MTA to cross the BBB was measured in an artificial membrane assay and using an in vitro cell model. Finally, in vivo tests were performed in models of hypoxic brain damage, Parkinson's disease and epilepsy. Results: MTA displays a wide array of neuroprotective activities against different insults in vitro. While the data from the two complementary approaches adopted indicate that MTA is likely to cross the BBB, the in vivo data showed that MTA may provide therapeutic benefits in specific circumstances. Whereas MTA reduced the neuronal cell death in pilocarpine-induced status epilepticus and the size of the lesion in global but not focal ischemic brain damage, it was ineffective in preserving dopaminergic neurons of the substantia nigra in the 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP)-mice model. However, in this model of Parkinson's disease the combined administration of MTA and an A(2A) adenosine receptor antagonist did produce significant neuroprotection in this brain region. Conclusion: MTA may potentially offer therapeutic neuroprotection.